Showing 141 - 160 results of 2,687 for search '"chemotherapy"', query time: 0.08s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147

    Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma by Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang

    Published 2021-01-01
    “…This paper is aimed at comparing the short-term efficacy of the combination of docetaxel, oxaliplatin, and capecitabine (DOX) with the combination of oxaliplatin and capecitabine (XELOX) as neoadjuvant chemotherapy regimens for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma. …”
    Get full text
    Article
  8. 148
  9. 149
  10. 150

    Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models by Willias Masocha

    Published 2018-01-01
    “…There is a scarcity of drugs to either prevent or properly manage chemotherapy-induced neuropathic pain (CINP). Cannabis or cannabinoids have been reported to improve pain measures in patients with neuropathic pain. …”
    Get full text
    Article
  11. 151
  12. 152

    Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma by Lana Bijelic, O. Anthony Stuart, Paul Sugarbaker

    Published 2012-01-01
    “…Cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) has emerged as optimal treatment for diffuse malignant peritoneal mesothelioma (DMPM) showing median survivals of 36–92 months. …”
    Get full text
    Article
  13. 153

    Weight variation gain and chemotherapy in women having breast cancer treated in the public health system by Samira Obeid Georges, Cinthya Costa Braga, Karine Anusca Martins

    Published 2014-07-01
    “…The aim of this study was to evaluate the influence of chemotherapy on weight change in women having breast cancer treated at a public hospital in Goiânia-GO. …”
    Get full text
    Article
  14. 154
  15. 155
  16. 156

    Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy by Dhanya Vasudevan, P. S. Jayalakshmy, Suresh Kumar, Siji Mathew

    Published 2015-01-01
    “…Paclitaxel based neoadjuvant chemotherapy regimen (NAT) in the setting of locally advanced breast cancer (LABC) can render inoperable tumor (T4, N2/N3) resectable. …”
    Get full text
    Article
  17. 157

    Urachal Carcinoma with Peritoneal Dissemination Treated with Chemotherapy and Surgical Resection Leading to Prolonged Survival with No Recurrence by Masato Yasui, Ryosuke Jikuya, Tomoyuki Tatenuma, Kentaro Muraoka, Susumu Umemoto, Masaki Kawai, Tsutomu Kouno, Takeshi Kishida

    Published 2018-01-01
    “…He received first-line chemotherapy with gemcitabine and cisplatin. After the fifth cycle, a computed tomography (CT) scan revealed abdominal fluid, and his serum tumor marker levels were increased. …”
    Get full text
    Article
  18. 158

    Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence by Irina Surovtsova, Felix J. F. Herth, Daria B. Kokh, Philipp Morakis

    Published 2025-12-01
    “…Background Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. …”
    Get full text
    Article
  19. 159
  20. 160

    Inadequate Lymph Node Yield: An Inadequate Indication for Adjuvant Chemotherapy in Stage II Colon Cancer by Alan Zambeli-Ljepović, MD, MHS, Daniel Hoffman, MD, Katherine E. Barnes, BS, Fernanda Romero-Hernandez, MD, Amir Ashraf Ganjouei, MD, MPH, Mohamed A. Adam, MD, Ankit Sarin, MD, MHA

    Published 2023-12-01
    “…Optimal therapy for stage II colon cancer remains unclear, and national guidelines recommend “consideration” of adjuvant chemotherapy (ACT) in the presence of high-risk features, including inadequate lymph node yield (LNY, <12 nodes). …”
    Get full text
    Article